Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer

Chung Lin Lee, Ying Hsu Chang, Chung Yi Liu, Ming Li Hsieh, Liang Kang Huang, Yuan Cheng Chu, Hung Cheng Kan, Po Hung Lin, Kai Jie Yu, Cheng Keng Chuang, Chun Te Wu, See Tong Pang, I. Hung Shao*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

2 Scopus citations

Abstract

Purpose: Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. Abiraterone acetate (AA), enzalutamide, and chemotherapy are first-line treatments for patients with mCRPC. This study examined prognostic factors for AA response in the form of prostate-specific antigen (PSA) kinetics throughout androgen-deprivation therapy (ADT) in chemonaïve patients with mCRPC. Materials and Methods: We retrospectively included data from 34 chemonaïve patients with mCRPC who had received AA at some point between January 2017 and December 2018. We separated patients into two study arms according to the decrease in PSA percentages after use of AA for 3 months. We correlated PSA kinetics parameters with response and compared the two study groups with respect to PSA kinetics. Results: The patients’ median age was 77 years. In the total group of patients, 64% had a response to AA, whereas 35% did not. The ratio of the PSA level at nadir to the level during ADT was significantly higher in the AA-sensitive group (19.78 vs. 1.03, p=0.019). Conclusions: Patients who experienced a dramatic change in PSA level during ADT were more likely to be resistant to AA after progression to mCRPC. Chemotherapy rather than AA might be more suitable as a first-line treatment for these patients.

Original languageEnglish
Pages (from-to)546-553
Number of pages8
JournalInvestigative and Clinical Urology
Volume63
Issue number5
DOIs
StatePublished - 01 09 2022

Bibliographical note

Publisher Copyright:
© The Korean Urological Association.

Keywords

  • Nonsteroidal anti-androgens
  • Prognosis
  • Prostate-specific antigen
  • Prostatic neoplasms

Fingerprint

Dive into the research topics of 'Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this